Summary of the year 2023

Summary of the year 2023

Inven2 is grateful to everyone who has contributed to building business and helping patients through new inventions, clarification, clinical studies, and commercial results. When someone is willing to pay for products, services, and values created when knowledge is...
Meet Inven2 at the Nordic Life Science Days

Meet Inven2 at the Nordic Life Science Days

The Nordic Life Science Days is the largest partnering conference for life sciences in the Nordic countries. Inven2 will participate with a joint Norwegian stand and in meetings with the industry to promote innovation projects from our portfolio. Feel free to contact...
Summary of 2022

Summary of 2022

In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by Else Marit Inderberg and Sébastien Wälchli’s research group at the Radium Hospital, Oslo University Hospital. ‘Clinical...